# A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

> **NCT01283906** · PHASE4 · COMPLETED · sponsor: **Access Pharmaceuticals, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Oral Mucositis

## Interventions

- **DEVICE:** MuGard
- **DEVICE:** Control Rinse

## Key facts

- **NCT ID:** NCT01283906
- **Lead sponsor:** Access Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-04
- **Final completion:** 2013-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283906, "A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01283906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*